| PRIMARY INFORMATION |
|---|
| ID | 1221 |
| PMID | 12712421 |
| Year | 2002 |
| Sequence | I/V-CLe-I/V-K-orn-I/V-fHdN |
| Name | Bacitracin |
| Length | 12 |
| N-Terminal Modification | Thiazoline ring |
| C-Terminal Modification | Free |
| Linear/ Cyclic | Cyclic |
| Chirality | Mix |
| Chemical Modification | Condensed aminoacids 1 and 2 forming thiazoline ring, orn=D-Ornithine, I/V= Ile or Val |
| Origin of Peptide | Produced as a mixture of closely related congeners by nonribosomal pathway catalyzed by large clusters of peptide and ketide synthetases and peptide/ketide “hybrid” synthetases, respectively |
| Nature of Peptide/Cargo | Bactericidal antibiotic often used topically. It is a cyclic peptide that contains positively and negatively charged lateral chains at neutral pH and is composed of a mixture of L and D amino acids. |
| Mechanism | Not mentioned |
| Cargo Sequence/Structure | None |
Name of cargo
| Not applicable |
| Assay | Fluorescein-labeled bacitracin and confocal microscopy, HPLC |
| Enhancer | 2.75 µL phloretin loaded PC-liposomes (30 mol % phloretin) |
| Properties of enhancer | Reduces the magnitude of the dipole potential in biological membranes |
| Concentration | After 12 h from liposome application, 75µL of bacitracin–FITC 100 µM phosphate buffer is applied |
| Incubation time | 48 Hours |
| Tissue permeability (value with units) | Bacitracin Cumulative Amount(µg/cm2)=82.1±4.4 |
| Tissue Sample | Human epidermis from abdominal sites of Caucasian females |
| Ex vivo/In vivo/In vitro | ex vivo |
| SECONDARY INFORMATION |
|---|
| STRUCTURE | |
| SMILES | N.A. |
